Copyright
©The Author(s) 2022.
World J Clin Cases. Jan 7, 2022; 10(1): 217-226
Published online Jan 7, 2022. doi: 10.12998/wjcc.v10.i1.217
Published online Jan 7, 2022. doi: 10.12998/wjcc.v10.i1.217
Table 3 Thrombectomy and thrombolysis therapy
| Measure | n (%) |
| Access (n = 24) | |
| Transhepatic | 13 (54.2) |
| Transjugular | 11 (45.8) |
| Thrombectomy (n = 12) | |
| Pharmacomechanical | 9 (75.0) |
| Aspiration | 3 (25.0) |
| Thrombolysis (n = 10) | |
| Thrombolytic agent | |
| tPA | 9 (90.0) |
| rtPA | 1 (10.0) |
| Infusion rate | |
| 1.0 mg/h | 5 (50.0) |
| 0.5 mg/h | 3 (30.0) |
| Fixed dose | 2 (20.0) |
| Infusion duration1 (n = 8) | |
| 24 h | 2 (25.0) |
| 48 h | 4 (50.0) |
| 72 h | 2 (25.0) |
- Citation: Alnahhal K, Toskich BB, Nussbaum S, Li Z, Erben Y, Hakaim AG, Farres H. Superior mesenteric venous thrombosis: Endovascular management and outcomes. World J Clin Cases 2022; 10(1): 217-226
- URL: https://www.wjgnet.com/2307-8960/full/v10/i1/217.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i1.217